

nab-PACLitaxel Monotherapy– 21 day

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	Reimbursement Status
Treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.	C50	00230a	Hospital

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances.

nab-PACLitaxel (is administered once every 21 days until disease progression or unacceptable toxicity develops. Discontinue treatment if no response after 2 cycles.

Facilities to treat anaphylaxis MUST be present when nab-PACLitaxel is administered.

Day	Drug	Dose	Route	Diluent & Rate	Cycle
1	nab-PACLitaxel	260mg/m ²	IV infusion	over 30mins	Repeat every 21days
<p>The use of medical devices containing silicone oil as a lubricant (i.e. syringes and IV bags) to reconstitute and administer nab-PACLitaxel may result in the formation of proteinaceous strands.</p> <p>Administer nab-PACLitaxel using an infusion set incorporating a 15 µm filter to avoid administration of these strands. Use of a 15 µm filter removes strands and does not change the physical or chemical properties of the reconstituted product. If strands are present and a filter is not available, the product must be discarded.</p>					

ELIGIBILITY:

- Indications as above
- ECOG status 0-2
- Life expectancy > 3 months

EXCLUSIONS:

- Hypersensitivity to nab-PACLitaxel, albumin, or to any of the excipients
- Patients who have progressed on prior taxane therapy
- Breast Feeding
- Severe hepatic impairment
- Grade ≥ 2 sensory or motor neuropathy

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist.

TESTS:

Baseline tests:

- FBC, renal and liver profile

NCCP Regimen: nab-PACLitaxel Monotherapy - 21days	Published: 05/04/2014 Review: 29/04/2025	Version number: 6
Tumour Group: Breast NCCP Regimen Code: 00230	ISMO Contributors: Prof Maccon Keane	Page 1 of 5

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

- Assessment of cardiac function, e.g. ECHO/MUGA scan if significant cardiac history or previous anthracycline therapy

Regular tests:

- FBC, renal and liver profile prior to each cycle
- Cardiac function if clinically indicated

Disease monitoring:

Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant.

Haematological:

Table 1: Dose modifications for neutropenia and/or thrombocytopenia

ANC (x10 ⁹ /L)		Platelets (x10 ⁹ /L)	Dose of nab-PAClitaxel
≥ 1.5	and	≥100	260mg/m ²
1-1.49	and	≥ 100	220mg/m ²
<1	OR	< 100	Delay until ANC ≥ 1.5 x10 ⁹ /L and platelets ≥ 100 x10 ⁹ /L, then consider giving 220mg/m ²

Table 2: Dose modifications for febrile neutropenia

First Occurrence	Delay until recovery (ANC ≥ 1.5 x10 ⁹ /L and platelets ≥ 100 x10 ⁹ /L), then dose reduce to 220mg/m²*
Second Occurrence	Delay until recovery (ANC ≥ 1.5 x10 ⁹ /L and platelets ≥ 100 x10 ⁹ /L), then dose reduce to 180mg/m²*

*Dose reductions should be maintained for subsequent cycles and not re-escalated.

NCCP Regimen: nab-PAClitaxel Monotherapy - 21days	Published: 05/04/2014 Review: 29/04/2025	Version number: 6
Tumour Group: Breast NCCP Regimen Code: 00230	ISMO Contributors: Prof Maccon Keane	Page 2 of 5

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

Renal and Hepatic Impairment:

Table 3: Dose modification of nab-PACLitaxel in renal and hepatic impairment

Renal Impairment		Hepatic Impairment			
CrCl (ml/min)	Dose	Bilirubin		AST	Dose
≥30 to <90	No dose adjustment necessary	> 1 to ≤ 1.5 x ULN	and	≤ 10 x ULN	No dose adjustment required
<30	Insufficient data available to make recommendation	> 1.5 to ≤ 5 x ULN	and	≤ 10 x ULN	20% dose reduction**
		>5 x ULN	or	>10 x ULN	Insufficient data to permit dosage recommendations

**The reduced dose may be escalated to the dose for patients with normal hepatic function if the patient is tolerating the treatment for at least two cycles

Management of adverse events:

Table 4: Dose Modifications for Adverse Events

Adverse reactions	Recommended dose modification
Grade ≥3 motor or sensory neuropathy First occurrence	Hold treatment until resolved to grade 2 or less, then reduce dose to 220mg/m ² ***
Second occurrence	Hold treatment until resolved to grade 2 or less, then reduce dose to 180mg/m ² ***
Grade 4 motor or sensory neuropathy First occurrence	Hold treatment until resolved to grade 2 or less, then reduce dose to 220mg/m ² ***
Second occurrence	Discontinue OR Hold treatment until resolved to grade 2 or less, then reduce dose to 180mg/m ² ***

***Dose reductions should be maintained for subsequent cycles and not re-escalated.

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL: Low (Refer to local policy).

PREMEDICATIONS: None usually required.

OTHER SUPPORTIVE CARE:

Myalgias and arthralgias may occur with PACLitaxel. Analgesic cover should be considered.

NCCP Regimen: nab-PACLitaxel Monotherapy - 21days	Published: 05/04/2014 Review: 29/04/2025	Version number: 6
Tumour Group: Breast NCCP Regimen Code: 00230	ISMO Contributors: Prof Maccon Keane	Page 3 of 5

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

nab-PAClitaxel is an albumin-bound nanoparticle formulation of PAClitaxel, which may have substantially different pharmacological properties compared to other formulations of PAClitaxel. It should not be substituted for or with other PAClitaxel formulations.

- **Hypersensitivity:** Rare occurrences of severe hypersensitivity reactions have been reported. If a hypersensitivity reaction occurs, the medicinal product should be discontinued immediately, symptomatic treatment should be initiated, and the patient should not be rechallenged with PAClitaxel.
- **Extravasation:** PAClitaxel causes pain and tissue necrosis if extravasated (**Refer to local policy**).
- **Neutropenia:** Bone marrow suppression (primarily neutropenia) occurs frequently with nab-PAClitaxel. Neutropenia is dose-dependent and a dose-limiting toxicity. Frequent monitoring of blood cell counts should be performed during nab-PAClitaxel therapy. Patients should not be retreated with subsequent cycles of until neutrophils recover to $>1.5 \times 10^9/L$ and platelets recover to $>100 \times 10^9/L$ (see Table 1).
- **Peripheral neuropathy:** Sensory neuropathy occurs frequently with nab-PAClitaxel, although development of severe symptoms is less common. If grade 3 sensory neuropathy develops, treatment should be withheld until resolution to grade 1 or 2 followed by a dose reduction for all subsequent courses of nab-PAClitaxel (see Table 4).
- **Hepatic Dysfunction:** Because the toxicity of PAClitaxel can be increased with hepatic impairment, administration of nab-PAClitaxel in patients with hepatic impairment should be performed with caution. nab-PAClitaxel is not recommended in patients that have total bilirubin $> 5 \times ULN$ or AST $> 10 \times ULN$.
- **Cardiotoxicity:** Rare reports of congestive heart failure and left ventricular dysfunction have been observed among individuals receiving nab-PAClitaxel. Most of the individuals were previously exposed to cardiotoxic medicinal products such as anthracyclines, or had underlying cardiac history.
- **Pneumonitis:** Even though the incidence is low, patients should be closely monitored for signs and symptoms of pneumonitis. During the conduct of a trial in metastatic pancreatic cancer, a higher rate of pneumonitis events was observed in patients receiving nab-PAClitaxel in combination with gemcitabine.

DRUG INTERACTIONS:

- Risk of drug interactions causing increased concentrations of PAClitaxel with CYP3A inhibitors. Patients should also be counselled with regard to consumption of grapefruit juice.
- Risk of drug interactions causing decreased concentrations of PAClitaxel with CYP3A inducers.
- Current drug interaction databases should be consulted for more information.

NCCP Regimen: nab-PAClitaxel Monotherapy - 21days	Published: 05/04/2014 Review: 29/04/2025	Version number: 6
Tumour Group: Breast NCCP Regimen Code: 00230	ISMO Contributors: Prof Maccon Keane	Page 4 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

REFERENCES:

1. Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. *J Clin Oncol* 2005;23(31):7794-803
2. BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using PACLitaxel-NAB (ABRAXANE®) BRAVABR October 2016.
3. MHRA, Drug Safety Update, Abraxane (paclitaxel, formulated as albumin-bound nanoparticles): potential presence of strands in intravenous infusion bag—if visible, filtration advised. February 2014, Available at <http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON377646>
4. NCCP Classification Document for Systemic AntiCancer Therapy (SACT) Induced Nausea and Vomiting. V3 2021. Available at: <https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp-classification-document-for-systemic-anti-cancer-therapy-sact-induced-nausea-and-vomiting.pdf>
5. Abraxane® (nab-PACLitaxel) Summary of Product Characteristics. Last updated: 09/03/2020. Accessed April 2020. Available at https://www.ema.europa.eu/en/documents/product-information/abraxane-epar-product-information_en.pdf
6. Pazenir® (nab-PACLitaxel) Summary of Product Characteristics. Last updated: 04/02/2020. Accessed 02/2022 https://www.ema.europa.eu/en/documents/overview/pazenir-epar-medicine-overview_en.pdf

Version	Date	Amendment	Approved By
1	05/04/2014		Prof Maccon Keane
2	29/04/2014	Updated advice on filters for administration	Prof Maccon Keane
3	08/04/2016	Updated dose modifications in renal and hepatic impairment and for adverse reactions (Table 1) as per SmPC	Prof Maccon Keane
4	18/04/2018	Updated with new NCCP regimen template, Updated hepatotoxicity adverse events as per SmPC	Prof Maccon Keane
5	29/04/2020	Reviewed.	Prof Maccon Keane
6	24/02/2022	Brand name Abraxane® removed. ATC codes removed. Updated reference section.	Prof Maccon Keane

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

NCCP Regimen: nab-PACLitaxel Monotherapy - 21days	Published: 05/04/2014 Review: 29/04/2025	Version number: 6
Tumour Group: Breast NCCP Regimen Code: 00230	ISMO Contributors: Prof Maccon Keane	Page 5 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		